Annals of Surgical Oncology

, Volume 26, Issue 12, pp 4002–4007 | Cite as

Utility of Early Postoperative Unstimulated Thyroglobulin in Influencing Decision Making in Patients with Papillary Thyroid Carcinoma

  • Alexandria D. McDowEmail author
  • Cynthia M. Shumway
  • Susan C. Pitt
  • David F. Schneider
  • Rebecca S. Sippel
  • Kristin L. Long
Endocrine Tumors



Serum thyroglobulin is used to screen for disease persistence or recurrence of papillary thyroid carcinoma (PTC). We sought to assess the utility of early postoperative unstimulated thyroglobulin levels (uTg) as a decision-making tool to guide the use of radioactive iodine (RAI) in PTC patients.


We performed a retrospective analysis of a prospectively maintained database of patients surgically treated for PTC from 2015 to 2017. We analyzed uTg approximately 6 weeks postoperatively. Patients undergoing total thyroidectomy or completion thyroidectomy were included in the study, and patients were analyzed according to postoperative uTg and receipt of RAI.


A total of 255 patients were analyzed, with 134 patients meeting the inclusion criteria. The median postoperative uTg was 0.3 ng/mL. Overall, 49.3% (66/134) of patients achieved the target uTg of ≤ 0.2 ng/mL at a mean time of 7.9 ± 0.3 weeks postoperatively; 60% (40/66) of patients who achieved uTg ≤ 0.2 ng/mL postoperatively did not receive RAI. A uTg ≤ 0.2 ng/mL was maintained at 6 months in 98.1% of patients, including 100% of patients who received RAI and 96.7% of patients who did not receive RAI (p = 0.8). Of those who did not receive RAI, none demonstrated structural disease recurrence on 6-month ultrasound. Patients with early postoperative uTg > 0.2–2.0 ng/mL showed benefit from RAI, while patients with uTg > 2.0 ng/mL did not achieve the targeted uTg level regardless of receipt of RAI.


Postoperative uTg may be used to guide the use of RAI. Achieving near-undetectable uTg within 6 weeks postoperatively could aid providers in assessing disease burden and minimize RAI use for patients with a low-risk of disease recurrence. Continued follow-up is necessary to accurately determine long-term outcomes.



  1. 1.
    Iñiguez-Ariza NM, Brito JP. Management of low-risk papillary thyroid cancer. Endocrinol Metab (Seoul) 2018;33(2):185–94.CrossRefGoogle Scholar
  2. 2.
    National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Thyroid Cancer. 2018. Accessed 16 Sep 2018.
  3. 3.
    Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19(11):1167–214.CrossRefGoogle Scholar
  4. 4.
    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26(1):1–133.CrossRefGoogle Scholar
  5. 5.
    Ibrahimpasic T, Nixon IJ, Palmer FL, et al. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer: Is there a need for radioactive iodine therapy? Surgery 2012;152(6):1095–105.CrossRefGoogle Scholar
  6. 6.
    Francis Z, Schlumberger M. Serum thyroglobulin determination in thyroid cancer patients. Best Pract Res Clin Endocrinol Metab 2008; 22(6):1039–46.CrossRefGoogle Scholar
  7. 7.
    Tuttle RM, Tala H, Shah J et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid association staging system. Thyroid 2010; 20(12):1341–49.CrossRefGoogle Scholar
  8. 8.
    Castagna MG, Maino F, Cipro C, Belardini V, Theodoropoulou A, Cevenini G, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 2011;165(3):441–6.CrossRefGoogle Scholar
  9. 9.
    Han JM, Kim WB, Yim JH et al. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid 2012; 22(8):784–90.CrossRefGoogle Scholar
  10. 10.
    Giovanella L, Maffioli M, Ceriani L, De Palma D, Spriano G. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma. Clin Chem Lab Med 2009; 47(8):1001–4.PubMedGoogle Scholar
  11. 11.
    Angell TE, Spencer CA, Rubino BD, Nicoloff JT, LoPresti JS. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid 2014; 24(7):1127–33.CrossRefGoogle Scholar
  12. 12.
    Bates MF, Lamas MR, Randle RW, Long KL, Pitt SC, Schneider DF, et al. Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease? Surgery 2018; 163(1):118–23.CrossRefGoogle Scholar
  13. 13.
    Orlov S, Salari F, Kashat L, Freeman JL, Vescan A, Witterick IJ, et al. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer. Endocrine 2015; 50:130–7.CrossRefGoogle Scholar
  14. 14.
    Adam MA, Thomas S, Youngwirth L, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg 2017; 265(2):402–7.CrossRefGoogle Scholar
  15. 15.
    Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol 2014; 21(12):3844–52.CrossRefGoogle Scholar
  16. 16.
    Oltmann SC, Schneider DF, Leverson G, Sivashanmugam T, Chen H, Sippel RS. Radioactive iodine remnant uptake after completion thyroidectomy: not such a complete cancer operation. Ann Surg Oncol 2014; 21(4):1379–83.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Alexandria D. McDow
    • 1
    Email author
  • Cynthia M. Shumway
    • 2
  • Susan C. Pitt
    • 2
  • David F. Schneider
    • 2
  • Rebecca S. Sippel
    • 2
  • Kristin L. Long
    • 2
  1. 1.Department of SurgeryIndiana University School of MedicineIndianapolisUSA
  2. 2.Department of SurgeryUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA

Personalised recommendations